DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival

Show full item record



Permalink

http://hdl.handle.net/10138/174563

Citation

Fleischer , T , Klajic , J , Aure , M R , Louhimo , R , Pladsen , A V , Ottestad , L , Touleimat , N , Laakso , M , Halvorsen , A R , Alnaes , G I G , Riis , M L H , Helland , A , Hautaniemi , S , Lonning , P E , Naume , B , Borresen-Dale , A-L , Tost , J & Kristensen , V N 2017 , ' DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival ' , Oncotarget , vol. 8 , no. 1 , pp. 1074-1082 . https://doi.org/10.18632/oncotarget.13718

Title: DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
Author: Fleischer, Thomas; Klajic, Jovana; Aure, Miriam Ragle; Louhimo, Riku; Pladsen, Arne V.; Ottestad, Lars; Touleimat, Nizar; Laakso, Marko; Halvorsen, Ann Rita; Alnaes, Grethe I. Grenaker; Riis, Margit L. H.; Helland, Aslaug; Hautaniemi, Sampsa; Lonning, Per Eystein; Naume, Bjorn; Borresen-Dale, Anne-Lise; Tost, Joerg; Kristensen, Vessela N.
Contributor: University of Helsinki, Research Programs Unit
University of Helsinki, Research Programs Unit
University of Helsinki, Research Programs Unit
Date: 2017-01-03
Language: eng
Number of pages: 9
Belongs to series: Oncotarget
ISSN: 1949-2553
URI: http://hdl.handle.net/10138/174563
Abstract: Breast cancer patients with Luminal A disease generally have a good prognosis, but among this patient group are patients with good prognosis that are currently overtreated with adjuvant chemotherapy, and also patients that have a bad prognosis and should be given more aggressive treatment. There is no available method for subclassification of this patient group. Here we present a DNA methylation signature (SAM40) that segregates Luminal A patients based on prognosis, and identify one good prognosis group and one bad prognosis group. The prognostic impact of SAM40 was validated in four independent patient cohorts. Being able to subdivide the Luminal A patients may give the two-sided benefit of identifying one subgroup that may benefit from a more aggressive treatment than what is given today, and importantly, identifying a subgroup that may benefit from less treatment.
Subject: breast cancer
Luminal A
DNA methylation
classification
prognosis
GENE-EXPRESSION PROFILES
MOLECULAR SUBTYPES
TUMORS
RISK
NORMALIZATION
DOXORUBICIN
RECURRENCE
PROGNOSIS
PATTERNS
DENSITY
3122 Cancers
1182 Biochemistry, cell and molecular biology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
DNA_methylation_signature.pdf 7.796Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record